A Phase 1/2 interventional study of IPH6501 in Non Hodgkin Lymphoma, sponsored by Innate Pharma. Terminated at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Innate Pharma · Phase 1/2, Interventional, and Treatment
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.
In Phase 1 - Dose finding, patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin lymphoma (NHL) will be enrolled. The dose finding part will include 2 sub-parts: Dose escalation will determine the Maximum Tolerated Dose (MTD) or the highest tested dose, Dose assessment will determine RP2D.
In Phase 2 - Dose expansion, one or more cohorts will be selected with patients with subtypes of advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin lymphoma.
1,989 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 307 are open to participants now.
This study's enrollment of 23 is below the median of 41 across 1,703 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Innate Pharma is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Main Inclusion criteria
Main Exclusion Criteria
Drug: IPH6501
phase 1 (dose finding) and phase 2 (dose expansion)
Safety and tolerability
To evaluate the safety profile (including dose limiting toxicities (DLT(s), the maximum tolerated dose (MTD) or highest tested dose), tolerability and determine the recommended phase 2 dose (RP2D)
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Objective Response Rate (ORR)
To investigate any preliminary antitumor activity
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Duration Of Response (DoR)
To investigate any preliminary antitumor activity
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Progression Free Survival (PFS)
To investigate any preliminary antitumor activity
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Maximum Observed Plasma Concentration (Cmax)
To characterize and evaluate the pharmacokinetic profile of IPH6501
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Area Under the Plasma Concentration (AUC)
To characterize and evaluate the pharmacokinetic profile of IPH6501
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Incidence of antidrug antibodies (ADA) against IPH6501
To evaluate the immunogenicity of IPH6501
Time frame: From time of informed consent through treatment period and including the follow-up: up to 22 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innate Pharma